Lenalidomide Generis (Lenalidomide)

Lenalidomide binds to cereblon, a component of the CRL4CRBN E3 ubiquitin ligase complex, changing its substrate specificity. This triggers the degradation of transcription factors Ikaros and Aiolos, leading to anti‑angiogenic, immunomodulatory, and anti‑proliferative effects that suppress malignant plasma cells and abnormal bone‑marrow clones.

The specific dose and schedule of Lenalidomide Generis are determined by the prescribing clinician based on the patient’s diagnosis, disease stage, renal function, and prior therapies. The prescriber will tailor the regimen to achieve optimal therapeutic benefit while minimizing risks.

Lenalidomide Generis is classified as pregnancy category X because it is known to cause fetal harm. It is contraindicated in pregnant women and should not be used by women who are or may become pregnant. Breastfeeding is also not recommended while on therapy.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Lenalidomide belongs to the immunomodulatory drug class, offering a distinct mechanism compared with proteasome inhibitors or monoclonal antibodies. It provides oral administration, which can be advantageous for outpatient care, and has demonstrated efficacy in both newly diagnosed and relapsed/refractory multiple myeloma settings.

Store Lenalidomide Generis at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct light, and ensure the container is tightly closed to maintain stability.

Lenalidomide Generis is taken orally, usually with or without food, as directed by the prescriber. The tablets should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed.

The most serious risks include thromboembolic events such as deep‑vein thrombosis, severe neutropenia leading to infection, hepatotoxicity, secondary malignancies, and rare but severe skin reactions like Stevens‑Johnson syndrome. Patients should be monitored closely for these events throughout therapy.

Lenalidomide Generis should not be used by pregnant women, individuals with known hypersensitivity to lenalidomide or its excipients, and patients with uncontrolled severe infections. Caution is also advised for those with significant renal or hepatic impairment, and the drug should be avoided in patients at high risk for thrombosis without appropriate prophylaxis.